Background and aim: Our study was aimed to compare multiphasic multi-detector computed tomography after secretin stimulation and mangafodipir trisodium-enhanced magnetic resonance imaging plus MR cholangiopancreatography in the characterization of solid pancreatic lesions. Patients and methods: Forty patients with ultrasound diagnosis of solid pancreatic lesion prospectively underwent both multi-detector computed tomography and magnetic resonance imaging. Three minutes after intravenous administration of secretin, post-contrast computed tomography scans were performed 40, 80, and 180s after contrast medium injection. MR protocol included axial/coronal, thin/thick-slab, single-shot T2w sequences and axial/coronal T1w breath-hold spoiled gradient-echo images before and 30-40 min after intravenous infusion of manganese clipyri-doxal diphosphate. Different observers blindly evaluated the ability of computed tomography and magnetic resonance imaging to characterize focal pancreatic lesions. Surgery, biopsy, and/or follow-up were considered as our diagnostic gold standard. Results: Thirty-five focal pancreatic lesions (adenocarcinoma, n = 18; focal chronic pancreatitis, It = 4; endocrine tumor, n = 6; metastasis, n = 1; cystic tumor, n = 3; indeterminate cystic lesions, n = 3) were present in 34 patients since the remaining 6 subjects showed no pathological finding. Both multi-detector computed tomography and magnetic resonance imaging showed a statistically significant correlation with the gold standard and between themselves in the characterization of 29 solid lesions of the pancreas (p<0.05). Conclusion: Both imaging techniques well correlate to final diagnosis of non-metastatic solid pancreatic lesions and particularly of adenocarcinomas with a slight advantage for mangafodipir trisodiumenhanced magnetic resonance imaging plus MR cholangiopancreatography. (C) 2009 Editrice Gastroenterologica Italiana S.r.I. Published by Elsevier Ltd. All rights reserved.
Secretin-stimulated multi-detector CT versus mangafodipir trisodium-enhanced MR imaging plus MRCP in characterization of non-metastatic solid pancreatic lesions
FAGGIONI L;BOGGI, UGO;BARTOLOZZI, CARLO;
2009-01-01
Abstract
Background and aim: Our study was aimed to compare multiphasic multi-detector computed tomography after secretin stimulation and mangafodipir trisodium-enhanced magnetic resonance imaging plus MR cholangiopancreatography in the characterization of solid pancreatic lesions. Patients and methods: Forty patients with ultrasound diagnosis of solid pancreatic lesion prospectively underwent both multi-detector computed tomography and magnetic resonance imaging. Three minutes after intravenous administration of secretin, post-contrast computed tomography scans were performed 40, 80, and 180s after contrast medium injection. MR protocol included axial/coronal, thin/thick-slab, single-shot T2w sequences and axial/coronal T1w breath-hold spoiled gradient-echo images before and 30-40 min after intravenous infusion of manganese clipyri-doxal diphosphate. Different observers blindly evaluated the ability of computed tomography and magnetic resonance imaging to characterize focal pancreatic lesions. Surgery, biopsy, and/or follow-up were considered as our diagnostic gold standard. Results: Thirty-five focal pancreatic lesions (adenocarcinoma, n = 18; focal chronic pancreatitis, It = 4; endocrine tumor, n = 6; metastasis, n = 1; cystic tumor, n = 3; indeterminate cystic lesions, n = 3) were present in 34 patients since the remaining 6 subjects showed no pathological finding. Both multi-detector computed tomography and magnetic resonance imaging showed a statistically significant correlation with the gold standard and between themselves in the characterization of 29 solid lesions of the pancreas (p<0.05). Conclusion: Both imaging techniques well correlate to final diagnosis of non-metastatic solid pancreatic lesions and particularly of adenocarcinomas with a slight advantage for mangafodipir trisodiumenhanced magnetic resonance imaging plus MR cholangiopancreatography. (C) 2009 Editrice Gastroenterologica Italiana S.r.I. Published by Elsevier Ltd. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
